Edition:
India

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

119.47USD
1:30am IST
Change (% chg)

$-0.45 (-0.38%)
Prev Close
$119.92
Open
$119.95
Day's High
$120.02
Day's Low
$119.26
Volume
1,449,623
Avg. Vol
2,317,408
52-wk High
$126.07
52-wk Low
$89.91

JNJ.N

Chart for JNJ.N

About

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company's segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care,... (more)

Overall

Beta: 0.62
Market Cap(Mil.): $328,086.31
Shares Outstanding(Mil.): 2,735.88
Dividend: 0.80
Yield (%): 2.67

Financials

  JNJ.N Industry Sector
P/E (TTM): 22.34 36.89 36.63
EPS (TTM): 5.37 -- --
ROI: 13.31 14.54 14.02
ROE: 20.93 15.38 14.98

Pfizer boosts cancer drug roster with $14 billion Medivation deal

Pfizer Inc , beating out numerous other bidders, said it agreed to buy U.S. cancer drug company Medivation Inc for $14 billion in cash, adding its blockbuster prostate cancer drug Xtandi to the company's growing oncology roster. | Video

23 Aug 2016

Pfizer boosts cancer drug roster with $14 billion Medivation deal

Pfizer Inc, beating out numerous other bidders, said it agreed to buy U.S. cancer drug company Medivation Inc for $14 billion in cash, adding its blockbuster prostate cancer drug Xtandi to the company's growing oncology roster.

23 Aug 2016

UPDATE 5-Pfizer boosts cancer drug roster with $14 bln Medivation deal

Aug 22 Pfizer Inc, beating out numerous other bidders, said it agreed to buy U.S. cancer drug company Medivation Inc for $14 billion in cash, adding its blockbuster prostate cancer drug Xtandi to the company's growing oncology roster.

23 Aug 2016

BRIEF-Johnson & Johnson reports 15 pct passive stake in Protagonist Therapeutics - SEC filing

* Johnson & Johnson reports 15.0 pct passive stake in Protagonist Therapeutics Inc as of Aug. 16 Source text (http://bit.ly/2biMrcb) Further company coverage:

19 Aug 2016

BRIEF-Johnson & Johnson announces ruling related to Remicade

* Johnson & Johnson announces ruling related to Remicade in the District of Massachusetts Federal Court hearing

17 Aug 2016

BRIEF-Paulson & Co raises share stake in Valeant, Facebook - SEC filing

* Ups share stake in Valeant Pharmaceuticals International Inc by 43.6 pct to 19.1 mln shares - SEC filing

16 Aug 2016

Future of drug pricing: paying for benefits not per pill

LONDON Global pressure on health spending is forcing the $1 trillion-a-year pharmaceutical industry to look for new ways to price its products: charging based on how much they improve patients' health, rather than how many pills or vials are sold.

09 Aug 2016

UPDATE 2-Drugmaker AbbVie bumps up profit forecast on strong Humira sales

July 29 AbbVie Inc posted higher-than-expected quarterly profit and revenue, driven by demand for its flagship drug Humira, and raised its earnings forecast for the year.

29 Jul 2016

BRIEF-Bristol-Myers Squibb collaborates with Johnson and Johnson for lung cancer research

* Bristol-Myers squibb announces new research collaboration with janssen in immuno-oncology focused on lung cancer

26 Jul 2016

J&J unit's former executives convicted of unapproved marketing

Two former executives of Acclarent Inc, a medical device company bought by Johnson & Johnson in 2010, were convicted on Wednesday by a U.S. jury on charges of promoting a product for an unapproved use.

21 Jul 2016

Earnings vs. Estimates